Journal of Clinical Oncology
Articles in this Issue
Treatment (Rx) patterns and outcomes with second-line (2L) therapy in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with cabozantinib plus nivolumab (cabo+nivo) or lenvatinib plus pembrolizumab (len+pem) in first-line (1L).
442 Background: Cabo+Nivo and Len+Pem are very effective and approved 1L Rx for pts with mccRCC [PMID:33657295, 33616314]....
Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Final results from a phase II study.
775 Background: Upper tract urothelial carcinoma (UTUC) carries a poor prognosis even after radical nephroureterectomy (RN...
Real-world effects of sodium-glucose cotransporter 2 inhibitor use on renal cell carcinoma.
480 Background: The Warburg effect has long been recognized as a key driver of cancer cell metabolism. Sodium–glucose cotr...
Overall survival in men with metastatic castration-resistant prostate cancer treated with olaparib or lutetium-177-PSMA-617 following prior systemic therapy.
202 Background: Both olaparib and lutetium-177-PSMA-617 have been approved for post-taxane and post-ARPI (androgen recepto...
Partial nephrectomy (PN) versus ablative therapies (AT) for T1a clear cell renal cell carcinoma (ccRCC): Analysis of 2,161 patients.
459 Background: PN is considered the standard treatment for T1a ccRCC, whereas AT have been increasingly utilized as minim...
Patterns of management and multidisciplinary care in high/very high and intermediate risk localized prostate cancer: A population-based study in Ontario, Canada.
333 Background: Patients with high- or very high-risk (H/vHR) localized prostate cancer (LPC) are at significantly increas...
Prognostic value of neutrophil-to-eosinophil ratio (NER) in patients with metastatic renal-cell carcinoma treated with immunotherapy.
457 Background: Nivolumab, a monoclonal antibody against PD-1, improved clinical outcomes compared to everolimus in metast...
Intratumoral mature TLSs to predict response to ICI rechallenge in non–clear cell renal cell carcinoma.
450 Background: While immune checkpoint inhibitor (lCl)-based therapy has shown promising efficacy in patients with metast...
Comparative treatment burden of BCG versus sequential gemcitabine and docetaxel for non-muscle-invasive bladder cancer: A time toxicity analysis.
730 Background: BCG shortages have necessitated alternative therapies for intermediate- and high-risk non-muscle-invasive...
Randomized trial of urinary tumor DNA (utDNA) testing-guided repeat transurethral resection (re-TURBT) in non-muscle-invasive bladder cancer (NMIBC): TRUCE-LB01.
TPS910 Background: Repeat transurethral resection of bladder tumor (re-TURBT) is a standard procedure for selected patient...
Androgen-receptor pathway inhibitors triplet therapy (ARAAT): Real-world outcomes in metastatic hormone-sensitive prostate cancer.
82 Background: Darolutamide or abiraterone, in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) is...
Adjuvant pembrolizumab in non–clear cell renal cell carcinoma after nephrectomy: An international multicenter study.
473 Background: KEYNOTE-564 demonstrated that adjuvant pembrolizumab improves outcomes after nephrectomy for clear-cell re...
Multimodal integration of VI-RADS, radiomics, and deep learning features for prediction of pathology and prognosis in bladder cancer.
640 Background: Recently, MRI-based assessments of bladder cancer using VI-RADS, radiomics, and deep learning models have...
Patterns and predictors of online cancer information seeking among urological cancer survivors.
328 Background: Online health information seeking is linked to improved patient engagement, knowledge, and shared decision...
SPPADE symptom burden and ePRO-based outcome prediction in patients with mCRPC treated with <sup>177</sup> Lu-PSMA-617 (LuPSMA).
142 Background: LuPSMA is a life-prolonging radioligand therapy that is widely considered to have favorable tolerability....
Inferring optimal MTAP homozygous loss (homozygous deletion) detection in urothelial cancer: Prevalence and co-alterations based upon treatment exposure and anatomical location.
641 Background: Validated homozygous loss detection is becoming increasingly important in clinical practice, with prostate...
Use of spatial transcriptomics to analyze the molecular landscape of tuberous sclerosis complex–associated angiomyolipoma: Implications for diagnosis and therapeutic targeting.
517 Background: Tuberous sclerosis complex–associated angiomyolipoma (TSC-AML) is often bilateral, multifocal, and sometim...
Real-world treatment transitions and healthcare resource utilization in patients with metastatic castration-resistant prostate cancer in Colombia.
49 Background: Although 10-20% PC patients in Latin America (LA) progress to mCRPC, real-world data describing mCRPC patie...
Impact of prior immune checkpoint inhibitor (ICI) and interval from ICI exposure on outcomes with enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).
704 Background: EVP is the preferred frontline regimen for patients (pts) with aUC. However, pivotal trials excluded pts w...
Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: Phase II single-arm trial (the CIPHER trial).
204 Background: Approximately one-fourth of patients with metastatic castration resistant prostate cancer (mCRPC) harbor m...
Correlation of adverse events (AEs) and clinical outcomes in first-line enfortumab vedotin–pembrolizumab (EVP) treatment for locally advanced or metastatic urothelial cancer (La/mUC).
717 Background: Neuropathy and rash are the most common AEs with EVP. Their association with clinical outcomes in standard...
Selective bladder preservation after neoadjuvant zanidatamab combined with tislelizumab and chemotherapy in patients with HER2-positive muscle-invasive bladder cancer (HARBOR): A multicenter study.
TPS887 Background: Muscle-invasive bladder cancer (MIBC) is a highly aggressive malignancy commonly treated with radical c...
Opportunities for precision oncology: Real-world patterns and disparities in FGFR3 testing among US patients with advanced urothelial cancer.
682 Background: Activating fibroblast receptor growth factor-3 (FGFR3) genetic alterations occur in 15-20% of LA/mUC and b...
National trends and predictors of inpatient palliative care utilization in metastatic prostate cancer.
71 Background: Men with metastatic prostate cancer (mPC) experience high symptom burden and often require intensive end-of...
Predicting the risk of prostate cancer metastasis at diagnosis in the VA Health Care System from H&E slides of the prostate needle biopsies.
128 Background: Men diagnosed with high-grade prostate cancer harbor increased rates of occult metastatic disease. We prop...